Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Non Operating Income: 2020-2025

Historic Non Operating Income for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $1.8 million.

  • Tango Therapeutics' Non Operating Income fell 52.14% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 39.86%. This contributed to the annual value of $15.5 million for FY2024, which is 23.39% up from last year.
  • According to the latest figures from Q3 2025, Tango Therapeutics' Non Operating Income is $1.8 million, which was down 16.15% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Non Operating Income ranged from a high of $4.4 million in Q1 2024 and a low of -$81,000 during Q4 2021.
  • For the 3-year period, Tango Therapeutics' Non Operating Income averaged around $3.2 million, with its median value being $3.3 million (2024).
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 210.96% in 2021, then surged by 2,023.46% in 2022.
  • Quarterly analysis of 5 years shows Tango Therapeutics' Non Operating Income stood at -$81,000 in 2021, then soared by 2,023.46% to $1.6 million in 2022, then skyrocketed by 175.80% to $4.3 million in 2023, then decreased by 23.46% to $3.3 million in 2024, then slumped by 52.14% to $1.8 million in 2025.
  • Its Non Operating Income was $1.8 million in Q3 2025, compared to $2.1 million in Q2 2025 and $2.7 million in Q1 2025.